Literature DB >> 11290772

ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement.

J L Riley1, P J Blair, J T Musser, R Abe, K Tezuka, T Tsuji, C H June.   

Abstract

We investigated the relationship between ICOS, CD28, CTLA-4, and IL-2 to gain a better understanding of this family of costimulatory receptors in the immune response. Using magnetic beads coated with anti-CD3 and varying amounts of anti-ICOS and anti-CTLA-4 Abs, we show that CTLA-4 ligation blocks ICOS costimulation. In addition to inhibiting cellular proliferation, CTLA-4 engagement prevented ICOS-costimulated T cells from producing IL-4, IL-10, and IL-13. Both an indirect and direct mechanism of CTLA-4's actions were examined. First, CTLA-4 engagement on resting cells was found to indirectly block ICOS costimulation by interferring with the signals needed to induce ICOS cell surface expression. Second, on preactivated cells that had high levels of ICOS expression, CTLA-4 ligation blocked the ICOS-mediated induction of IL-4, IL-10, and IL-13, suggesting an interference with downstream signaling pathways. The addition of IL-2 not only overcame both mechanisms, but also greatly augmented the level of cellular activation suggesting synergy between ICOS and IL-2 signaling. This cooperation between ICOS and IL-2 signaling was explored further by showing that the minimum level of IL-2 produced by ICOS costimulation was required for T cell proliferation. Finally, exogenous IL-2 was required for sustained growth of ICOS-costimulated T cells. These results indicate that stringent control of ICOS costimulation is maintained initially by CTLA-4 engagement and later by a requirement for exogenous IL-2.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11290772     DOI: 10.4049/jimmunol.166.8.4943

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

Review 1.  Activation and inhibition of lymphocytes by costimulation.

Authors:  Kenneth A Frauwirth; Craig B Thompson
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

2.  The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity.

Authors:  Hiroshi Harada; Alan D Salama; Masayuki Sho; Atsushi Izawa; Sigrid E Sandner; Toshiro Ito; Hisaya Akiba; Hideo Yagita; Arlene H Sharpe; Gordon J Freeman; Mohamed H Sayegh
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

Review 3.  Costimulation of Th17 cells: Adding fuel or putting out the fire in the inflamed gut?

Authors:  Zili Zhang; James T Rosenbaum; Wenwei Zhong; Carmen Lim; David J Hinrichs
Journal:  Semin Immunopathol       Date:  2010-01-30       Impact factor: 9.623

Review 4.  Approaches to studying costimulation of human antiviral T cell responses: prospects for immunotherapeutic vaccines.

Authors:  Lena Serghides; Mariana Vidric; Tania H Watts
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 5.  Germinal-center organization and cellular dynamics.

Authors:  Christopher D C Allen; Takaharu Okada; Jason G Cyster
Journal:  Immunity       Date:  2007-08       Impact factor: 31.745

Review 6.  Signals that drive T follicular helper cell formation.

Authors:  Louise M C Webb; Michelle A Linterman
Journal:  Immunology       Date:  2017-07-17       Impact factor: 7.397

7.  CTLA-4 gene exon-1 +49 A/G polymorphism: lack of association with autoimmune disease in patients with common variable immune deficiency.

Authors:  Adina Kay Knight; Davide Serrano; Yaron Tomer; Charlotte Cunningham-Rundles
Journal:  J Clin Immunol       Date:  2006-12-28       Impact factor: 8.317

Review 8.  T cell costimulation, checkpoint inhibitors and anti-tumor therapy.

Authors:  Dipankar Nandi; Sanmoy Pathak; Taru Verma; Madhulika Singh; Avik Chattopadhyay; Samriddhi Thakur; Abinaya Raghavan; Abhijeet Gokhroo
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

9.  Involvement of inducible costimulator ligand (ICOSL) expression in thyroid tissue in hyperthyroidism of Graves' disease patients.

Authors:  Fengming Wang; Tao Yan; Lujun Chen; Xuemin Chen; Tong Liu; Shuang Shen; Ting Li; Li Gao; Ting Wang; Jing Sun; Cuiping Liu; Haorong Wu; Xueguang Zhang; Lei Chen
Journal:  J Clin Immunol       Date:  2012-06-17       Impact factor: 8.317

10.  Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin.

Authors:  Samik Basu; Tatiana Golovina; Tatiana Mikheeva; Carl H June; James L Riley
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.